Laboratory markers evolution in patients with persistent detection of SARS-CoV-2
e202305039
Keywords:
Persistence, Laboratory markers, Biomarkers, SARS-CoV-2Abstract
BACKGROUND // The study of the evolution of certain biomarkers in patients with persistent detection of SARS-CoV-2 could determine the profile of the pathology that these patients may suffer. The objective of this study was to describe the evolution of different laboratory markers in patients with persistent detection of SARS-CoV-2, and determining these parameters were into reference values.
METHODS // Patients were divided into two groups: the control group (G0) included patients with a positive direct test for SARS-CoV-2 followed by 2 negative, while the problem group (G1) included patients with at least 3 consecutive positive tests. The time between consecutive samples was five to twenty days, and only patients with negative serology were included. Demographic data, comorbidities, symptoms, radiology and hospitalization were collected, as well as data from analytic and blood gases. The comparison between the study groups was realized using the t-student and U Mann-Whitney test for quantitative variables, and the χ2 test for qualitative variables. Results with p<0.05 were taken as significant.
RESULTS // Ninety patients were included, thirty-eight in G0 and fifty-two in G1. D-dimer decreased 10.20 times more in G0 patients, and normal levels of this parameter at t1 were 1.46 times more frequent in these patients. The percentage of lymphocytes increased sixteen times more in G0, and the normal values in t1 were 10.40 times more common in these patients. C-reactive protein decreased significantly in both groups, and lactate increased more in G1 patients.
CONCLUSIONS // The results of the study suggest that some biomarkers evolve differently in patients with persistent detection of SARS-CoV-2, which may have significant clinical impact. This information could help to determine the main organs or systems affected, allowing to anticipate socio-sanitary measures to prevent or compensate these alterations.
Downloads
References
Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S et al. A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. New England Journal of Medicine [Internet]. 15 de mayo de 2003 [citado 3 de agosto de 2020];348(20):1953-1966. Disponible en: https://dx.doi.org/10.1056/NEJMoa030781
Legido-Quigley H, Mateos-García JT, Campos VR, Gea-Sánchez M, Muntaner C, McKee M. The resilience of the Spanish health system against the COVID-19 pandemic. Lancet Public Health [Internet]. mayo de 2020 [citado 5 de agosto de 2020];5(5):e251-252. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104264/
Langford BJ, So M, Raybardhan S, Leung V, Soucy JPR, Westwood D et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. abril de 2021;27(4):520-531.
Qian GQ, Chen XQ, Lv DF, Ma AHY, Wang LP, Yang NB et al. Duration of SARS-CoV-2 viral shedding during COVID-19 infection. Infectious Diseases [Internet]. 2 de julio de 2020 [consultado 5 de agosto de 2020];52(7):511-2. Disponible en: https://dx.doi.org/10.1080/23744235.2020.1748705
Fu Y, Li Y, Guo E, He L, Liu J, Yang B et al. Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19: A Retrospective Study. Ann Intern Med. abril de 2021;174(4):453-461.
Cento V, Colagrossi L, Nava A, Lamberti A, Senatore S, Travi G et al. Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients. J Infect [Internet]. septiembre de 2020 [citado 4 de agosto de 2021];81(3):e90-2. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836522/
Chang D, Zhao P, Zhang D, Dong JH, Xu Z, Yang G et al. Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19. J Allergy Clin Immunol Pract. septiembre de 2020;8(8):2585-2591.e1.
Li TZ, Cao ZH, Chen Y, Cai MT, Zhang LY, Xu H et al. Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19. J Med Virol. enero de 2021;93(1):506-512.
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. marzo de 2021;19(3):141-154.
Velazquez S, Madurga R, Castellano JM, Rodriguez-Pascual J, de Aguiar Diaz Obregon SR, Jimeno S et al. Hemogram-derived ratios as prognostic markers of ICU admission in COVID-19. BMC Emerg Med. 27 de julio de 2021;21(1):89.
Chen X, Zhu B, Hong W, Zeng J, He X, Chen J et al. Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. Int J Infect Dis. septiembre de 2020;98:252-260.
Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W et al. Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 28 de julio de 2020;71(15):799-806.
Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. mayo de 2020;35(5):1545-1549.
Tutorial para evaluación e informe de la radiografía de pacientes COVID-19 [Internet]. SERAM | 35 Congreso Nacional SERAM, Edición virtual 19-26 mayo 2021. [consultado 28 de julio de 2021]. Disponible en: https://seram.es/index.php/informacion/noticias/1424-tutorial-para-evaluacion-e-informe-de-la-radiografia-de-torax-en-la-infeccion-covid-19?iccaldate=2020-04-1
Silva Andrade B, Siqueira S, de Assis Soares WR, de Souza Rangel F, Santos NO, Dos Santos Freitas A et al. Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses. 18 de abril de 2021;13(4):700.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 28 de marzo de 2020;395(10229):1054-1062.
Lehmann A, Prosch H, Zehetmayer S, Gysan MR, Bernitzky D, Vonbank K et al. Impact of persistent D-dimer elevation following recovery from COVID-19. PLOS ONE [Internet]. 28 de octubre de 2021 [consultado 13 de enero de 2022];16(10):e0258351. Disponible en: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0258351
Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol. 15 de octubre de 2002;169(8):4288-4297.
Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, Nemati M. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions. Life Sci. 15 de septiembre de 2020;257:118102.
Eissa M, Shaarawy S, Abdellateif MS. The Role of Different Inflammatory Indices in the Diagnosis of COVID-19. Int J Gen Med. 2021;14:7843-7853.
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 28 de julio de 2020;71(15):762-768.
Huang W, Wu Q, Chen Z, Xiong Z, Wang K, Tian J et al. The potential indicators for pulmonary fibrosis in survivors of severe COVID-19. J Infect. febrero de 2021;82(2):e5-7.
Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). octubre de 2021;53(10):737-754.
Alamdari DH, Moghaddam AB, Amini S, Keramati MR, Zarmehri AM, Alamdari AH et al. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. Eur J Pharmacol. 15 de octubre de 2020;885:173494.
Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020;11:1446.
Nematswerani N, Collie S, Chen T, Cohen M, Champion J, Feldman C et al. The impact of routine pulse oximetry use on outcomes in COVID-19-infected patients at increased risk of severe disease: A retrospective cohort analysis. S Afr Med J. 3 de septiembre de 2021;111(10):950-956.
Núñez I, Soto-Mota A. Heterogeneity of hypoxemia severity according to pulse oximetry and blood gas analysis in COVID-19 pneumonia. Med Intensiva [Internet]. 27 de octubre de 2021 [consultado 18 de enero de 2022]; Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549438/
Gupta B, Jain G, Chandrakar S, Gupta N, Agarwal A. Arterial Blood Gas as a Predictor of Mortality in COVID Pneumonia Patients Initiated on Noninvasive Mechanical Ventilation: A Retrospective Analysis. Indian J Crit Care Med [Internet]. agosto de 2021 [consultado 18 de enero de 2022];25(8):866-71. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559762/
Masyuk M, Wernly B, Lichtenauer M, Franz M, Kabisch B, Muessig JM et al. Prognostic relevance of serum lactate kinetics in critically ill patients. Intensive Care Med. enero de 2019;45(1):55-61.
Bruno RR, Wernly B, Flaatten H, Fjølner J, Artigas A, Bollen Pinto B et al. Lactate is associated with mortality in very old intensive care patients suffering from COVID-19: results from an international observational study of 2,860 patients. Ann Intensive Care [Internet]. 21 de agosto de 2021 [citado 18 de enero de 2022];11:128. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379577/
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 José María López-Pintor Huertas, Óscar Herráez Carrera, Javier Sánchez-López, Jorge Gaitán Pitera, María Huertas Vaquero, Antonio Tejera-Muñoz, Ángel Arias-Arias, María Ángeles Asencio Egea
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
